ZURICH, July 19 (Reuters) - Roche's Japanese subsidiary Chugai said on Tuesday subcutaneous injection of its Actemra drug has shown efficacy in rheumatoid arthritis compared to intravenous infusion.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback